Therapeutic Momentum

The Therapeutic Momentum podcast series illuminates the inspiring personal stories, touchstone moments, and transformational events that fuel the relentless pursuit of life-changing treatments. It reveals the intricate tapestry of experiences that drive people in the biomedical field who share the collective goal of improving patient outcomes. We hope to offer listeners a multifaceted perspective on the diverse talent and backgrounds of people working towards better health and hope for patients.

Therapeutic Momentum is a science podcast hosted by Unknown Host, with 8 episodes on record and a Required Pod Score of 80. PitchCentric scores this show on Booking Probability, Listen Score, and live audience signals refreshed every 24 hours.

Unknown Host hosts Therapeutic Momentum, a science show with 8 episodes published.

Our AI reads these to draft pitches. Use them as grounding for a pitch that cites a real guest and a specific topic.

• 

  Episode #7

  Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

  May 16, 202654 minS0

  <p>In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both...

  ListenShow Notes
• 

  Therapeutic Momentum

  Kate Haviland: The Bilingual Biotech Leader Behind Blueprint's $9.5B Sanofi Deal

  May 16, 202654 min

  In this episode I am joined by Kate Haviland, who most recently served as President and CEO of Blueprint Medicines, guiding it from a clinical-stage company through a fully integrated commercial business and ultimately through its roughly $9.5 billion acquisition by Sanofi in 2025. Over a more than twenty-year career spanning Genzyme, PTC Therapeutics, Sarepta, Idera, and Blueprint, Kate has built a reputation for bridging rigorous science with sharp business instincts, equally fluent in the lab and the boardroom. She studied biochemistry and economics at Wesleyan, earned her MBA at Harvard Business School, and today serves as Board Chair of both Fulcrum Therapeutics and GC Therapeutics, as a director at Bicara and Avalyn, and on the board of BIO. This episode was recorded in 2025

  ListenShow Notes
• 

  Therapeutic Momentum

  AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

  Apr 11, 202658 minS0

  <p>In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences.</p><p>We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views...

  ListenShow Notes
• 

  Therapeutic Momentum

  AI + Life Sciences: Why the Future Needs Both Human Brains and Wet Labs

  Apr 11, 202658 min

  In this episode, I speak with Sam Scarpino, Director of AI and Life Sciences at Northeastern University's Institute for Experiential AI and Professor of Public Health and Health Sciences. With a background spanning evolutionary biology, pandemic response during H1N1, and pathogen surveillance at the Rockefeller Foundation, Sam offers a distinctive perspective on artificial intelligence in the life sciences. We discuss the fundamental limitations of AI in biological systems, the irreplaceable role of wet lab experimentation, and how human-AI collaboration can address challenges from rural oncology access to rare disease drug development. Sam also shares his views on why current debates around AGI distract from the urgent work of building responsible AI tools today.

  ListenShow Notes
• 

  Episode #6

  Robert Plenge - Finding Truth & Making Medicines

  Jan 18, 20261 hourS0

  <p>Robert Plenge is a physician-scientist known for his work at Merck, Celgene, and BMS, translating insights from human genetics into breakthroughs in drug discovery and development, resulting in new medicines. On his well-known blog, he writes with inspiring clarity about genomics, therapeutic target validation, and lessons from translational research, bridging academic rigor and industry practice for scientists and clinicians alike. In this interview, we explore Robert's passion for causal human biology, drug development, and leading teams. </p><p>Roberts Blog: https://www.robertplenge.com</p>

  ListenShow Notes

Recent guests on Therapeutic Momentum. Study who booked and why before you pitch.

Based on semantic analysis of episode topics and host coverage, this show is a strong guest fit for executives in:

Industry fit is computed by PitchCentric using vector embeddings of the show's episode catalog.